Clearmind Medicine(CMND.US)

Last Updated 19:00:00 ET
longbridge loading

Clearmind Medicine Announces 1-for-10 Reverse Stock Split; Stock Down

nasdaq·
US
CMND
-37.83%
US
PBE
+0.11%
US
BIB
+0.05%
nasdaq·
US
CMND
-37.83%
US
PBE
+0.11%
US
BIB
+0.05%

Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications | CMND Stock News

StockTitan·
US
CMND
-37.83%
US
LLY
+3.37%
StockTitan·
US
CMND
-37.83%
US
LLY
+3.37%

Clearmind Medicine CEO Dr. Adi Zuloff-Shani named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.C. | CMND Stock News

StockTitan·
US
CMND
-37.83%
US
VHT
+0.97%
US
BIB
+0.05%
StockTitan·
US
CMND
-37.83%
US
VHT
+0.97%
US
BIB
+0.05%

Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder | CMND Stock News

StockTitan·
US
CMND
-37.83%
StockTitan·
US
CMND
-37.83%

Clearmind Medicine Announces “Inside MEAI” Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trial | CMND Stock News

StockTitan·
US
CMND
-37.83%
US
ARKG
+0.04%
US
LABU
-2.35%
StockTitan·
US
CMND
-37.83%
US
ARKG
+0.04%
US
LABU
-2.35%

Clearmind Medicine shares are trading lower. The company announced filing of a European patent application for psychedelic compounds targeting the treatment of Post-Traumatic Stress Disorder and other mental health disorders.

benzinga_article·
US
CMND
-37.83%
benzinga_article·
US
CMND
-37.83%

Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD | CMND Stock News

StockTitan·
US
CMND
-37.83%
StockTitan·
US
CMND
-37.83%
© 2026 Longbridge｜Disclaimer